Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts assign Pyxis Oncology an average recommendation of Moderate Buy (seven analysts: five buys, one hold, one sell) with a consensus 12‑month price target of $7.00, although several firms recently cut targets and ratings.
• Pyxis beat quarterly expectations, reporting EPS of ($0.29) versus estimates of ($0.35) and revenue of $11.04 million versus a $0.13 million consensus, yet analysts still forecast a full‑year EPS of -1.04.
• The stock opened at $1.70 with a market cap of about $106.8 million, a 52‑week range of $0.87–$5.55, and roughly 39.07% of shares held by institutional investors.

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.00.

PYXS has been the subject of a number of research analyst reports. Royal Bank Of Canada cut their price target on Pyxis Oncology from $8.00 to $5.00 and set an "outperform" rating for the company in a report on Thursday, December 18th. Wall Street Zen cut Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday, April 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday, March 24th. Finally, Stifel Nicolaus cut their price target on Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, March 24th.

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS opened at $1.70 on Friday. The stock has a market cap of $106.81 million, a PE ratio of -1.32 and a beta of 1.41. The business has a fifty day moving average of $1.46 and a two-hundred day moving average of $2.46. Pyxis Oncology has a 52-week low of $0.87 and a 52-week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter, compared to the consensus estimate of $0.13 million. Analysts predict that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Maia Wealth LLC acquired a new stake in Pyxis Oncology in the fourth quarter worth about $25,000. Fox Run Management L.L.C. acquired a new stake in Pyxis Oncology in the fourth quarter worth about $26,000. Engineers Gate Manager LP acquired a new stake in Pyxis Oncology in the fourth quarter worth about $26,000. Avanza Fonder AB acquired a new stake in Pyxis Oncology in the fourth quarter worth about $31,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Pyxis Oncology in the third quarter worth about $77,000. 39.07% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.